Financial Performance - Net income for the six months ended June 30, 2019, was approximately $1,456,000, compared to a net loss of approximately $2,897,000 for the same period in 2018 [156]. - Net cash provided by operating activities for the six months ended June 30, 2019, was $990,000, compared to net cash used of $4,171,000 for the same period in 2018 [157]. - The Company continues to incur losses, and achieving profitability depends on the successful development, approval, and commercialization of its product candidates [167]. Revenue and Collaboration - Collaboration revenue for the six months ended June 30, 2019, was $5,670,000, compared to $0 for the same period in 2018, primarily from the Merck Collaboration Agreement [143]. - The company entered into a Collaboration Agreement with Merck for the development of influenza A/B antiviral agents, with Merck funding the research and development [142]. - The Company is relying on continued collaboration with Merck, which is critical for its future progress [170]. Expenses - Research and development expenses for the six months ended June 30, 2019, were $1,969,000, remaining comparable to $1,997,000 for the same period in 2018 [145]. - General and administrative expenses for the six months ended June 30, 2019, were approximately $2,374,000, an increase of $169,000 from $2,205,000 for the same period in 2018 [148]. Cash Position and Funding - As of June 30, 2019, the company had approximately $7.2 million in cash on hand, which may not be sufficient to cover operating costs for the next 12 months [162]. - The company has not yet established a source of revenue sufficient to cover its operating costs and has incurred significant operating losses since inception [160]. - Management intends to fund future operations through additional private or public equity offerings, which may be dilutive to existing shareholders [167]. Clinical Development - The company has identified promising antiviral compounds for influenza, HCV, and norovirus infections, focusing on CC-31244 as a potential best-in-class treatment for HCV [134]. - The Phase 2a clinical study of CC-31244 for HCV treatment showed that 8 of 12 subjects achieved the primary efficacy endpoint of sustained virologic response at 12 weeks after treatment [136]. Risks and Accounting - There are risks associated with the availability of products manufactured by third parties and the ability of clinical research organizations to recruit subjects [170]. - The Company has disclosed critical accounting policies and estimates in its Annual Report on Form 10-K for the year ended December 31, 2018 [171].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Large accelerated filer [ ] Accelerated filer [X] Non-accelerated filer [ ] Smaller reporting company [X] Emerging growth company [ ] Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock COCP The Nasdaq Stock Market LLC (The Nasdaq Capital Market) FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR [ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-55158 Cocrystal Pharma, Inc. | --- | --- | |--------------------------------------------------------------------------------------------------|----------------------------- ...